HSP90AA1 and colorectal carcinoma: CRC patients with a strong Hsp90α/β-positive primary tumor showed shorter progression-free survival (PFS, p = 0.033, Figure 2A) and reduced overall survival (OS, p = 0.059, Figure 2B).